BR112012023974A2 - composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. - Google Patents

composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto.

Info

Publication number
BR112012023974A2
BR112012023974A2 BR112012023974A BR112012023974A BR112012023974A2 BR 112012023974 A2 BR112012023974 A2 BR 112012023974A2 BR 112012023974 A BR112012023974 A BR 112012023974A BR 112012023974 A BR112012023974 A BR 112012023974A BR 112012023974 A2 BR112012023974 A2 BR 112012023974A2
Authority
BR
Brazil
Prior art keywords
compound
faah
treating
disease
pharmaceutical composition
Prior art date
Application number
BR112012023974A
Other languages
English (en)
Inventor
Kreatsoulas Constantine
Foster Shalen Evan
P Moore Keith
G Nantermet Philippe
Yang Zhiqiang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112012023974A2 publication Critical patent/BR112012023974A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composto, composição farmacêutica, método de tratar uma doença mediada com faah,e, uso de um composto. a presente invenção está direcionada a ceros derivados de oxazol que são úteis como moduladores da amida hidrolase de ácido graxo (faah) e como agentes de formação de imagem faah. a invenção também está envolvida com formulações farmacêuticas que compreendem estes compostos como ingredientes ativos e com o uso dos compostos e suas formulações no tratamento de certos distúrbios, incluindo osteoartrite, artrite reumatoide, neuropatia diabética, neuralgia pós-herpética, dor esquelotomuscular, e fibromialgia, assim como dor aguda, enxaqueda, distúrbio do sono, doença de alzheimer, e doença de parkinson.
BR112012023974A 2010-04-08 2011-04-04 composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. BR112012023974A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32199210P 2010-04-08 2010-04-08
PCT/US2011/031040 WO2011126960A1 (en) 2010-04-08 2011-04-04 Oxazole derivatives useful as modulators of faah

Publications (1)

Publication Number Publication Date
BR112012023974A2 true BR112012023974A2 (pt) 2017-09-26

Family

ID=44763231

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023974A BR112012023974A2 (pt) 2010-04-08 2011-04-04 composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto.

Country Status (8)

Country Link
US (1) US9193697B2 (pt)
EP (1) EP2555772B1 (pt)
JP (1) JP2013523814A (pt)
CN (1) CN102917704A (pt)
AU (1) AU2011238487B2 (pt)
BR (1) BR112012023974A2 (pt)
CA (1) CA2793900A1 (pt)
WO (1) WO2011126960A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001313A (es) * 2008-08-04 2011-03-04 Merck Sharp & Dohme Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos.
US9006433B2 (en) 2010-04-21 2015-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
MX2019009310A (es) 2017-02-08 2019-12-09 Bayer Ag Derivados de triazoletiona.
US20200045967A1 (en) 2017-02-08 2020-02-13 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
EP3580210A1 (en) 2017-02-08 2019-12-18 Bayer CropScience Aktiengesellschaft Triazole derivatives and their use as fungicides
BR112019016517A2 (pt) 2017-02-10 2020-04-14 Bayer Ag combinações de composto ativo
CN110831593A (zh) 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
CN110804048A (zh) * 2019-11-08 2020-02-18 暨南大学 恶唑酮类化合物及其应用、faah的正电子药物
JP2023502123A (ja) 2019-11-19 2023-01-20 トレベナ・インコーポレイテッド Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2023728A4 (en) * 2006-05-26 2010-11-24 Janssen Pharmaceutica Nv OXAZOLYLPIPERIDINES AS MODULATORS OF FATTY ACID AMIDHYDROLASE
FR2921063B1 (fr) 2007-09-13 2009-12-11 Sod Conseils Rech Applic Ligands des recepteurs cannabinoides
WO2009152025A1 (en) * 2008-06-11 2009-12-17 Merck & Co., Inc. Imidazole derivatives useful as inhibitors of faah
MX2011001313A (es) * 2008-08-04 2011-03-04 Merck Sharp & Dohme Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos.
MX2012008801A (es) * 2010-01-28 2012-08-17 Merck Sharp & Dohme Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones.

Also Published As

Publication number Publication date
US20130018048A1 (en) 2013-01-17
CN102917704A (zh) 2013-02-06
EP2555772B1 (en) 2017-01-11
CA2793900A1 (en) 2011-10-13
EP2555772A4 (en) 2013-08-28
EP2555772A1 (en) 2013-02-13
JP2013523814A (ja) 2013-06-17
WO2011126960A1 (en) 2011-10-13
US9193697B2 (en) 2015-11-24
AU2011238487B2 (en) 2015-10-01
AU2011238487A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
BR112012023974A2 (pt) composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto.
BR112012023971A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BR112012028055A2 (pt) composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada
BR112012018913A2 (pt) "composição farmacêutica, e, uso da composição"
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
TW200740801A (en) N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
MA33299B1 (fr) Nouvelle formulation de naproxène
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
NZ610689A (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
AR104638A1 (es) Insecticida de arilpirrolidina, proceso para su preparación y su uso como principio activo para combatir plagas de animales
BR112012017994A2 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
EA201290856A1 (ru) Стабилизированная фармацевтическая композиция

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]